Larimar Therapeutics paid its 3 named executives $5.1M in total in FY2024 (Dec). CEO Carole S. Ben-Maimon, M.D. was paid $2.5M of that.
Pay$100 in the stock at the end of FY21 → $36
Pay of each named executive
Carole S. Ben-Maimon, M.D.President and Chief Executive Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
3 years
Michael CelanoChief Financial Officer and Secretary
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
3 years
Gopi Shankar, Ph.D., MBA, FAAPSChief Development Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
3 years
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.